DAM
MRVI icon

DLD Asset Management’s Maravai LifeSciences MRVI Stock Holding History

DLD Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75,000
Closed -$3.68M – 184
2021
Q3 		$3.68M Buy
+75,000
New +$3.66M 0.27% 54

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

DLD Asset Management's MRVI Position: Q4 2021 in Review

DLD Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 75,000 shares — an estimated $3.68M sold.

DLD Asset Management first reported a position in MRVI in Q3 2021 and held it in 1 quarter. The position peaked at $3.68M in Q3 2021. 228 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

  • DLD Asset Management reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
  • DLD Asset Management sold 75,000 Maravai LifeSciences shares in Q4 2021, an estimated $3.68M.
  • DLD Asset Management first reported a position in Maravai LifeSciences in Q3 2021 and held it in 1 quarter.
  • DLD Asset Management's Maravai LifeSciences position peaked at $3.68M in Q3 2021.
  • 228 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on DLD Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.